Category Archives: Public Policy

Latest From Public Policy

Tomorrow: From Volume to Value: Designing a Patient-Centered Healthcare System (Webcast)

new-bio-logo

Tomorrow at the Newseum, The Hill will be hosting a live discussion about the transition from volume-based to value-based care. A live webcast will be available for the event, which begins at 8:30 am ET. Last week, Jim Robinson, President of Astellas Pharma US, shared his thoughts in a related op-ed at The Hill. Biopharmaceutical innovation is transforming what it means to be a patient battling some of our most difficult diseases, such as cancer, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Know Your IP Strategy: A Necessity for Technology Start-ups

Annemarie_Meike

The Licensing Executives Society Foundation invites start-up companies, with investments of less than $200,000, and graduate students from around the world to participate in their annual International Business Plan Competition. The Competition requires participants to submit a business plan with an intellectual property component and strategies explaining how intellectual property will be used to achieve business objectives. Before the first round submission deadline, the Competition pairs registered teams with senior leaders in the intellectual property Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post

Patently Biotech’s Top Articles of 2015

Intellectual property and patent reform have dominated headlines in 2015. As we close out the year, let’s take a look at some of this year’s most memorable Patently BIOtech coverage. Here are Patently Biotech’s top blog posts of 2015: This Independence Day, Let’s Thank the Inventors IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma FDA Acts on Biosimilars Seventy Nine House Members Express Concern with H.R. 9 Make sure Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post

Patent Reform in the News

© 2010 Opensourceway (CC 2.0 Attribution ShareAlike) (flickr.com/photos/opensourceway/)

The New York Post and The Washington Post have both run Op-eds in the last week addressing the need to reform the PTO’s inter partes review (IPR) process within current patent reform legislative efforts. Both opinions point to the weakness within the IPR process exposed by short selling practices of predatory hedge fund managers. Click on the links below to read more: From the New York Post: Hedge-fund investors are coming to raid your medicine cabinet. By Peter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

A National Blueprint for Biodefense Released Today

ebola

A major report was released today detailing findings and recommendations to improve the U.S. biodefense readiness. “A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts” was authored by the Blue Ribbon Study Panel on Biodefense, on which BIO President and CEO Jim Greenwood serves. The panel is co-chaired by former Sen. Joe Lieberman and former Gov. Tom Ridge. Other panelists include former Secretary of Health and Human Services Donna Shalala, former Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,